Aquestive Therapeutics (AQST) Stock Price, News & Analysis

Company Overview

Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a pharmaceutical company specializing in advanced drug delivery platforms designed to improve the safety, efficacy and patient compliance of existing therapies and novel compounds. The company’s proprietary PharmFilm, LiquiFilm, AeroFilm and VosoFilm technologies facilitate oral, buccal and pulmonary administration of drugs via thin polymeric films. These platforms seek to minimize peak-to-trough fluctuations in blood plasma levels, offer rapid onset of action and reduce reliance on traditional oral or injectable dosage forms.

Lead commercial offering Sympazan (diazepam buccal film) was approved by the U.S. Food and Drug Administration in 2020 for the acute treatment of seizure clusters in patients with epilepsy. Aquestive’s development pipeline features Libervant, an improved diazepam buccal film formulation currently under regulatory review, and Qtrypta, a sublingual film candidate for acute migraine management. Additional programs address central nervous system disorders, endocrine therapies and anti-infective treatments, leveraging the versatility of its film-based delivery systems.

Headquartered in Warren, New Jersey, Aquestive integrates research and development, clinical affairs, regulatory strategy and manufacturing under one roof. The company maintains strategic partnerships and licensing agreements to extend its geographic footprint, collaborating with contract manufacturers and specialty pharmaceutical firms to reach markets across North America, Europe and Asia. Aquestive continues to explore new indications and formulations that capitalize on its platform technologies.

Originally founded as MonoSol Rx in 2004 and rebranded as Aquestive in 2012 ahead of its 2015 initial public offering, the company is led by CEO William “Bill” Lewis, who brings over two decades of experience in pharmaceutical development and commercialization. The leadership team comprises executives with deep expertise in drug development, regulatory affairs and commercial operations, positioning Aquestive to advance its innovative delivery solutions and expand its market presence in the years ahead.

Key Stats

• Today's Range: $3.66 to $3.80
• 50-Day Range: $2.22 to $3.72
• 52-Week Range: $2.12 to $5.80
• Volume: 1.89 million shs
• Average Volume: 1.50 million shs
• Market Capitalization: $367.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.14
• Consensus Rating: Buy

Aquestive Therapeutics Stock Analysis - MarketRank™

Aquestive Therapeutics scored higher than 27% of companies evaluated by MarketBeat, and ranked 784th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Aquestive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Aquestive Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Aquestive Therapeutics are expected to decrease in the coming year, from ($0.46) to ($0.56) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aquestive Therapeutics is -6.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aquestive Therapeutics is -6.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.18% of the float of Aquestive Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aquestive Therapeutics has a short interest ratio ("days to cover") of 7.9.

Change versus previous month

Short interest in Aquestive Therapeutics has recently increased by 7.72%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aquestive Therapeutics does not currently pay a dividend.

Dividend Growth

Aquestive Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

13.18% of the float of Aquestive Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aquestive Therapeutics has a short interest ratio ("days to cover") of 7.9.

Change versus previous month

Short interest in Aquestive Therapeutics has recently increased by 7.72%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.39

News Sentiment

Aquestive Therapeutics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Aquestive Therapeutics this week, compared to 3 articles on an average week.

Search Interest

5 people have searched for AQST on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Aquestive Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aquestive Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.85% of the stock of Aquestive Therapeutics is held by insiders.

Percentage Held by Institutions

Only 32.45% of the stock of Aquestive Therapeutics is held by institutions.

AQST Stock Analysis - Frequently Asked Questions

How have AQST shares performed this year?

Aquestive Therapeutics' stock was trading at $3.56 on January 1st, 2025. Since then, AQST shares have increased by 3.9% and is now trading at $3.70.

How were Aquestive Therapeutics' earnings last quarter?

Aquestive Therapeutics, Inc. (NASDAQ:AQST) posted its quarterly earnings results on Monday, May, 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by $0.07. The company had revenue of $8.72 million for the quarter, compared to analyst estimates of $12.23 million.
Read the conference call transcript.

When did Aquestive Therapeutics IPO?

Aquestive Therapeutics (AQST) raised $60 million in an initial public offering (IPO) on Wednesday, July 25th 2018. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.

How do I buy shares of Aquestive Therapeutics?

Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aquestive Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aquestive Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and GE Aerospace (GE).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/07/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AQST
• CIK: 1398733
• Web: www.aquestive.com
• Phone: (908) 941-1900
• Fax: N/A
• Employees: 160
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.14
• High Stock Price Target: $17.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +174.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$44.14 million
• Net Margins: -100.02%
• Pretax Margin: -100.05%
• Return on Equity: N/A
• Return on Assets: -50.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.87
• Quick Ratio: 4.48

Sales & Book Value

• Annual Sales: $57.56 million
• Price / Sales: 6.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.66) per share
• Price / Book: -5.61

Miscellaneous

• Outstanding Shares: 99,330,000
• Free Float: 91,531,000
• Market Cap: $367.52 million
• Optionable: Optionable
• Beta: 1.97